Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730813 | 0.96 | AGTR1 (0.57) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL5773556 | 0.94 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL4960875 | 0.93 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL14169520 | 0.93 | AGTR1 (0.53) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6755888 | 0.93 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL4814768 | 0.92 | AGTR1 (0.60) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL5774766 | 0.92 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Methyl Isobutyl Ketone SCHEMBL6755889 | 0.92 | AGTR2 (0.57) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL5360591 | 0.92 | AGTR1 (0.52) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL12730668 | 0.91 | AGTR1 (0.52) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076281-A1 | PROCESS FOR THE PREPARATION OF LOSARTAN AND ITS SALTS | MEDICHEM, S.A. (ES) | 2009-03-19 | — | — | US | claimed |
| EP-1891055-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM | Medichem, S.A. (ES) | 2008-02-27 | — | — | EP | claimed |
| WO-2007020533-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM | MEDICHEM, S.A. (US) | 2007-02-22 | — | — | WO | claimed |
| US-7041832-B2 | Processes for preparing losartan and losartan potassium | TAVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-09 | — | — | US | claimed |
| EP-1474417-B1 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMA (IL) | 2006-03-22 | — | — | EP | claimed |
| EP-1474417-A2 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-10 | — | — | EP | claimed |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-02-19 | — | — | US | claimed |
| WO-2003093262-A2 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-13 | — | — | WO | claimed |
| EP-0643704-B1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | DU PONT (US) | 2003-09-17 | — | — | EP | claimed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | claimed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250360106-A1 | PREVENTING IMMUNOTHERAPY-INDUCED EDEMA USING ANGIOTENSIN RECEPTOR BLOCKERS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-11-27 | — | — | US | disclosed |
| US-12383508-B2 | High-purity peg lipids and uses thereof | MODERNATX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
| US-5206374-A | Process for preparing tetrazolylphenylboronic acid intermediates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5130439-A | Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY, A CORPORATION OF DELAWARE | 1992-07-14 | — | — | US | disclosed |
| EP-0470795-A1 | Process for the manufacture of nitriles | ZENECA LIMITED (GB) | 1992-02-12 | — | — | EP | disclosed |
| EP-0470794-A1 | Process for the preparation of nitriles | ZENECA LIMITED (GB) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | REN, ACE, AGT | AGTR1 4/4885AGTR2 6/4885ABCC4 4052/4885 |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LNPEP, AUP1, PLTP | AGTR1 4252/4885AGTR2 4496/4885ABCC4 1478/4885 |
| US-12383508-B2 | High-purity peg lipids and uses thereof | LIPA, HDLBP, PLTP | AGTR1 4479/4885AGTR2 4304/4885ABCC4 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.